Poor water solubility and low bioavailability of active pharmaceutical ingredients (APIs) are major causes of friction in the pharmaceutical industry and represent a formidable hurdle for pharmaceutical drug development. Drug delivery remains the major challenge for the application of new small-molecule drugs as well as biopharmaceuticals. The three challenges for synthetic delivery systems are: (i) controlling drug distribution and clearance in the blood; (ii) solubilizing poorly water-soluble agents, and (iii) selectively targeting specific tissues. Although several polymer-based systems have addressed the first two demands and have been translated into clinical practice, no targeted synthetic drug delivery system has reached the market. This Review is designed to provide a background on the challenges and requirements for the design and translation of new polymer-based delivery systems. This report will focus on chemical approaches to drug delivery for systemic applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091760PMC
http://dx.doi.org/10.1002/anie.202203942DOI Listing

Publication Analysis

Top Keywords

drug delivery
16
delivery systems
12
chemical approaches
8
synthetic drug
8
systemic applications
8
drug
6
delivery
6
approaches synthetic
4
systems
4
systems systemic
4

Similar Publications

Camptothecin: a key building block in the design of anti-tumor agents.

Future Med Chem

January 2025

School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China.

View Article and Find Full Text PDF

Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use.

View Article and Find Full Text PDF

Block copolymer (BCP) microparticles, which exhibit rapid change of morphology and physicochemical property in response to external stimuli, represent a promising avenue for the development of programmable smart materials. Among the methods available for generating BCP microparticles with adjustable morphologies, the confined assembly of BCPs within emulsions has emerged as a particularly facile and versatile approach. This review provides a comprehensive overview of the role of responsive surfactants in modulating interfacial interactions at the oil-water interface, which facilitates controlled BCP microparticle morphology.

View Article and Find Full Text PDF

Gene Therapy for Glioblastoma Multiforme.

Viruses

January 2025

Surgical Neurology Branch, NINDS, NIH 10 Center Drive, Bethesda, MD 20892, USA.

Glioblastoma multiforme (GBM) is a devastating, aggressive primary brain tumor with poor patient outcomes and a five-year survival of less than 10%. Significant limitations to effective GBM treatment include poor drug delivery across the blood-brain barrier, drug resistance, and complex genetic tumor alterations. Gene therapy uses a mechanism different from other GBM therapies to reduce tumor growth and enhance antitumor immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!